The results of Study 403, which Intra-Cellular Therapies is set to present, could potentially influence the company's future developments and strategies. This, in turn, could impact the company's stock performance, depending on whether the results are positive or negative. However, without specific details on the study's results, it's difficult to predict the exact impact on the stock.